Information Provided By:
Fly News Breaks for July 19, 2016
Jul 19, 2016 | 08:37 EDT
SunTrust says that the delay of Akorn's (AKRX) ephedrine injectable could make Flamel (FLML) the sole supplier of about 5M ephedrine vials. The firm estimates that the delay will boost the value of Flamel's stock by up to $3 per share if it does not raise the price of its injectable and by up to $8 per share if it does raise the price. The firm keeps a $31 price target and Buy rating on Flamel.
News For FLML;AKRX From the Last 2 Days
There are no results for your query FLML;AKRX